FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2444-2451 December 7, 2006 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.

A 44-year-old woman with chronic hepatitis C has intermittent fatigue and persistent elevations in serum alanine aminotransferase levels. She has had hepatitis C for 10 years. The diagnosis was made after she attempted to donate blood and was found . . . [Full Text of this Article]

The Clinical Problem

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.

Address reprint requests to Dr. Hoofnagle at Bldg. 31, Rm. 9A27, 31 Center Dr., National Institutes of Health, Bethesda, MD 20892, or at hoofnaglej@extra.niddk.nih.gov.

Related Letters:

Peginterferon and Ribavirin for Hepatitis C
Duggan A. E., Duggan J. M., Assy N., Embon O., Evoli A., Servidei S., Ben Salem C., Hmouda H., Bouraoui K., Leiner S., Abramowicz M., Hoofnagle J. H., Seeff L. B.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:1269-1271, Mar 22, 2007. Correspondence

This article has been cited by other articles:

• Govindarajan, R., Endres, C. J., Whittington, D., LeCluyse, E., Pastor-Anglada, M., Tse, C.-M., Unadkat, J. D. (2008). Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G570-G580 [Abstract] [Full Text]  
• Yang, W., Zhao, Y., Fabrycki, J., Hou, X., Nie, X., Sanchez, A., Phadke, A., Deshpande, M., Agarwal, A., Huang, M. (2008). Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors. Antimicrob. Agents Chemother. 52: 2043-2052 [Abstract] [Full Text]  
• Liu, C-H, Liang, C-C, Lin, J-W, Chen, S-I, Tsai, H-B, Chang, C-S, Hung, P-H, Kao, J-H, Liu, C-J, Lai, M-Y, Chen, J-H, Chen, P-J, Kao, J-H, Chen, D-S (2008). Pegylated interferon {alpha}-2a versus standard interferon {alpha}-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 57: 525-530 [Abstract] [Full Text]  
• Cross, T J S, Antoniades, C G, Harrison, P M (2008). Current and future management of chronic hepatitis C infection. Postgrad. Med. J. 84: 172-176 [Abstract] [Full Text]  
• Kanda, T., Steele, R., Ray, R., Ray, R. B. (2007). Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes. J. Virol. 81: 12375-12381 [Abstract] [Full Text]  
• Noueiry, A. O., Olivo, P. D., Slomczynska, U., Zhou, Y., Buscher, B., Geiss, B., Engle, M., Roth, R. M., Chung, K. M., Samuel, M., Diamond, M. S. (2007). Identification of Novel Small-Molecule Inhibitors of West Nile Virus Infection. J. Virol. 81: 11992-12004 [Abstract] [Full Text]  
• Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J. A., Castelblanco, N., Rosen, H. R. (2007). Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction. J. Virol. 81: 9249-9258 [Abstract] [Full Text]  
• Liang, T. J. (2007). Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 -- Is Less More?. NEJM 357: 176-178 [Full Text]  
• Duggan, A. E., Duggan, J. M., Assy, N., Embon, O., Evoli, A., Servidei, S., Ben Salem, C., Hmouda, H., Bouraoui, K., Leiner, S., Abramowicz, M., Hoofnagle, J. H., Seeff, L. B. (2007). Peginterferon and Ribavirin for Hepatitis C. NEJM 356: 1269-1271 [Full Text]